The Translational Breast Cancer Research Consortium was well represented at the 2018 SABCS Meeting. Presentations included:

Evaluation of Multiple Transcriptomic Gene Risk Signatures in Male Breast Cancer (TBCRC 029); Abstract #P16-19-01

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive (HR+) Metastatic Breast Cancer (MBC) with Prior Chemotherapy for Advanced Disease (TBCRC 035):A Phase II Study with Pharmacodynamic Markers; Abstract #PD2-12

A Randomized Phase II Study of Pembrolizumab in Combination with Carboplatin versus Carboplatin Alone in Breast Cancer Patients with Chest Wall Disease, with Immunologic and Genomic Correlative Studies (TBCRC 044); Abstract #OT3-04-04